Source | Drug | JSpA patients (n) | Study duration | Outcomea | Study design |
---|---|---|---|---|---|
Henrickson [37] | ETNERCEPT | 8 | 24Â months | improvementb | Open-label Uncontrolled |
Tse [38] | ETANERCEPT | 2 | Â | Â | Â |
 | INFLIXIMAB | 8 | 12 months | improvement | Open-label Uncontrolled |
Sulpice [39] | Â | 20 (23 treatments) | Â | Â | Â |
 | ETANERCEPT | 19 | 12 months | improvement | Retrospective Cohort |
 | INFLIXIMAB | 3 |  |  |  |
 | ADALIMUMAB | 1 |  |  |  |
Otten [40] | Â | 22 (24 treatments) | Â | Â | Â |
 | ETANERCEPT | 20 |  |  |  |
 | INFLIXIMAB | 2 | 24 months | improvement | Multicenter Observational Register |
 | ADALIMUMAB | 2 |  |  |  |
Horneff [41] | ADALIMUMAB | 17 | 6Â months | improvement | Double-Blind Placebo-controlled |
Horneff [42] | ETANERCEPT | 122 | 3Â months | improvement | Open-label |
 |  |  |  |  | Uncontrolled |
Burgos Vargas [43] | ADALIMUMAB | 46 | 12Â months | improvement | Double-Blind Placebo-controlled |
Hugle B [44] | INFLIXIMAB | 10 | 84Â months | Â | Open-label |
 | ETANERCEPT | 6 |  | improvement | Observational |
Horneff G [45] | ETANERCEPT | 41 | 12Â months | improvement | Double-Blind Placebo- controlled |